Reith, John D.
March 2011
Journal of Bone & Joint Surgery, American Volume;3/16/2011, Vol. 93-A Issue 6, p608
Academic Journal
In this article, the author discusses the article "Interferon-α/β Receptor as a Prognostic Maker in Osteosarcoma" by Tadahiko Kubo and colleagues. The author says that the improvements in terms of the survival for osteosarcoma patients are considered to begin through the application of neoadjuvant chemotherapy regimens. He mentions that the use of the drug doxorubicin from P-glycoprotein has been known to effectively remove the tumor cells and treat osteosarcoma patients.


Related Articles

  • Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein. Fa Zhang; Ling Zhang; Chun Zhang; Wan Lu // Pharmaceutical Research;Apr2009, Vol. 26 Issue 4, p914 

    Abstract Purpose  Naringenin has shown paradoxical results to modulate the function of multidrug resistance-associated proteins (MRPs). The aim of this study is to interpret whether naringenin can reverse intrinsic and/or acquired resistance of cancer cells to chemotherapeutic agents. ...

  • Astragaloside IV reduces the expression level of P glycoprotein in multidrug resistant human hepatic cancer cell lines. PEI-PEI WANG; DU-JUAN XU; CAN HUANG; WEI-PING WANG; WEN-KEXU // Molecular Medicine Reports;2014, Vol. 9 Issue 6, p2131 

    Astragaloside is a saponin widely used in traditional Chinese medicine and has been reported to be a potent multidrug resistance (MDR) reversal agent. The present study investigated the role of astragaloside IV (ASIV) in the regulation of P-glycoprotein (P-gp, encoded by the mdrl gene) and its...

  • Cancer multidrug resistance. Persidis, Aris // Nature Biotechnology;Jan1999, Vol. 17 Issue 1, p94 

    Discusses the effect of multidrug resistance in the failure of chemotherapy drugs. Conferring of chemoresistance in cancer through P-glycoprotein and multidrug resistance-associated protein (MRP); Details of the multidrug resistance programs offered by selected companies; Correlation between...

  • Doxorubicin-cisplatin chemotherapy for high-grade Nonosteogenic Sarcoma of bone. Comparison of treatment and control groups. Waddell, Andrea E.; Davis, Aileen M.; Ahn, Henry; Wunder, Jay S.; Blackstein, Martin E.; Bell, Robert S. // Canadian Journal of Surgery;Jun99, Vol. 42 Issue 3, p190 

    Evaluates the role of chemotherapy with a combination of doxorubicin and cisplatin in high-grade, nonosteogenic, non-Ewing's sarcoma of the bone. Surgical interventions; Comparison of disease-free survival and overall survival rate of patients with or without chemotherapy; Relapse incidence...

  • The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Scotlandi, Katia; Manara, Maria Cristina; Serra, Massimo; Benini, Stefania; Maurici, Daniela; Caputo, Antonella; De Giovanni, Carla; Lollini, Pier-Luigi; Nanni, Patrizia; Picci, Piero; Campanacci, Mario; Baldini, Nicola // Oncogene;1/21/99, Vol. 18 Issue 3, p739 

    The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein...

  • Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. Susa, Michiro; Iyer, Arun K.; Ryu, Keinosuke; Choy, Edwin; Hornicek, Francis J.; Mankin, Henry; Milane, Lara; Amiji, Mansoor M.; Zhenfeng Duan // PLoS ONE;2010, Vol. 5 Issue 5, p1 

    Background: The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients' average 5 year survival rate from 20% to 70% in the past 30 years. However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance...

  • Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells. McNealy, Tamara L.; Trojan, Lutz; Knoll, Thomas; Alken, Peter; Michel, Maurice Stephan // Urological Research;Aug2004, Vol. 32 Issue 4, p255 

    The use of doxorubicin as a chemotherapeutic agent is hindered by its toxic side effects on the normal cells of the body. The objective of this study was to determine if micelle-delivered doxorubicin could increase the effectiveness of doxorubicin against prostate carcinoma cells. Rat prostate...

  • La chimiothérapie des ostéosarcomes. Brugières, L.; Piperno-Neumann, S. // Oncologie;Feb2007, Vol. 9 Issue 2, p164 

    Current standard treatments for osteosarcoma are based on a combination of polychemotherapy and tumour resection. Progression-free rates are now 65 to 70% in most recent studies of patients with operable, non-metastatic osteosarcoma. Most chemotherapy protocols involve high-dose methotrexate in...

  • ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cheol-Hee Choi // Cancer Cell International;2005, Vol. 5, p30 

    One of the major problems related with anticancer chemotherapy is resistance against anticancer drugs. The ATP-binding cassette (ABC) transporters are a family of transporter proteins that are responsible for drug resistance and a low bioavailability of drugs by pumping a variety of drugs out...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics